Identifying biotech stock to invest in
Identifying the best biotech stocks to buy or the best biotechnology stocks to invest in isn’t always as easy as picking a four-letter stock symbol. Clinical trials are not always positive, and in many cases, a negative result can produce a considerable downfall in a biotechnology company. In turn, the underlying biotech stock could fall as well. Regulatory concerns from agencies like the Food And Drug Administration keep tight constraints on biotechnology companies. It is crucial for investors to make sure they are fully aware of what the FDA guidelines are so that these investors can make good investments.
Generally speaking, biotech stocks are a mainstay among growth investors. The rewards can be jaw-dropping – prices on biotechnology shares can double or more overnight – but with this reward also comes a level of risk that is just as high. It’s not unusual for these stocks to be cut in half or more if drug-trial data disappoints or a drug application is rejected by the FDA.
In the end, it’s vital for anyone looking to invest in biotech stocks or those looking to learn how to trade biotechnology stocks to pay attention to everything going on within the industry. Though many of these biotech stocks can see strong momentum trading, it’s also important to note that depending on the catalyst for the move, it can last for a short period or months on end.
Some examples of biotech stocks in the US stock market that you can look up:
1) Jasper: A new stem-cell conditioning agent
Jasper Therapeutics $JSPR is a clinical-stage biotech company that went public last month through a deal with the special purpose acquisition company Amplitude Healthcare Acquisition (NASDAQ: AMHC). The biotech's shares have gained an eye-popping 99.7% in just the past week, thanks to coverage from the investment bank Oppenheimer.
Long story short, this unique therapy may be able to overcome the limitations associated with the current regimen of toxic agents used for conditioning before treatment with these life-saving therapies. JSP191, in effect, could become an integral part of the standard of care for patients undergoing these cutting-edge procedures for a wide range of blood disorders and rare diseases.
2) NRx Pharmaceuticals: A potential breakthrough in the treatment of severe COVID cases
NRx Pharmaceuticals' $NRXP value proposition centers on its severe COVID treatment called Zyesami (aviptadil). The company and its shareholders are hoping that the FDA will greenlight the drug soon in light of its impressive performance in the clinic.
What's the upside potential? COVID-19 is expected to morph into an endemic respiratory illness. That means there will be a consistent need for novel coronavirus drugs -- especially for hospitalized patients with severe forms of the disease -- for a long time to come. Now, NRx still has a lot of work to do to get the drug on the market.
One more stock that I like more than these TWO is Regencell Bioscience $RGC.
Regencell Bioscience is an early-clinical bioscience company which focuses on the research and development of Traditional Chinese Medicine (TCM) to holistically treat neurocognitive disorders and also infectious diseases which affects the immune system such as COVID-19.
The company have been researching and conducting studies to address the fundamental causes of ADHD and ASD disorders. The goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the treatment of these disorders. $rgc aim to achieve improvements in both symptoms and overall health of patients as compared to currently available medications in the market. They are passionate about transforming the lives of patients, their families and caregivers and help them feel their best physically, mentally and emotionally!
RGC’s steady share price ascension in recent weeks may be a sign of greater things to come as its moves towards commercialization, we are encouraged by its thoughtful, systematic approach to developing its therapies, and communicating its progress to shareholders.
https://www.nasdaq.com/articles/2-biotech-sto...2021-10-17
Identifying the best biotech stocks to buy or the best biotechnology stocks to invest in isn’t always as easy as picking a four-letter stock symbol. Clinical trials are not always positive, and in many cases, a negative result can produce a considerable downfall in a biotechnology company. In turn, the underlying biotech stock could fall as well. Regulatory concerns from agencies like the Food And Drug Administration keep tight constraints on biotechnology companies. It is crucial for investors to make sure they are fully aware of what the FDA guidelines are so that these investors can make good investments.
Generally speaking, biotech stocks are a mainstay among growth investors. The rewards can be jaw-dropping – prices on biotechnology shares can double or more overnight – but with this reward also comes a level of risk that is just as high. It’s not unusual for these stocks to be cut in half or more if drug-trial data disappoints or a drug application is rejected by the FDA.
In the end, it’s vital for anyone looking to invest in biotech stocks or those looking to learn how to trade biotechnology stocks to pay attention to everything going on within the industry. Though many of these biotech stocks can see strong momentum trading, it’s also important to note that depending on the catalyst for the move, it can last for a short period or months on end.
Some examples of biotech stocks in the US stock market that you can look up:
1) Jasper: A new stem-cell conditioning agent
Jasper Therapeutics $JSPR is a clinical-stage biotech company that went public last month through a deal with the special purpose acquisition company Amplitude Healthcare Acquisition (NASDAQ: AMHC). The biotech's shares have gained an eye-popping 99.7% in just the past week, thanks to coverage from the investment bank Oppenheimer.
Long story short, this unique therapy may be able to overcome the limitations associated with the current regimen of toxic agents used for conditioning before treatment with these life-saving therapies. JSP191, in effect, could become an integral part of the standard of care for patients undergoing these cutting-edge procedures for a wide range of blood disorders and rare diseases.
2) NRx Pharmaceuticals: A potential breakthrough in the treatment of severe COVID cases
NRx Pharmaceuticals' $NRXP value proposition centers on its severe COVID treatment called Zyesami (aviptadil). The company and its shareholders are hoping that the FDA will greenlight the drug soon in light of its impressive performance in the clinic.
What's the upside potential? COVID-19 is expected to morph into an endemic respiratory illness. That means there will be a consistent need for novel coronavirus drugs -- especially for hospitalized patients with severe forms of the disease -- for a long time to come. Now, NRx still has a lot of work to do to get the drug on the market.
One more stock that I like more than these TWO is Regencell Bioscience $RGC.
Regencell Bioscience is an early-clinical bioscience company which focuses on the research and development of Traditional Chinese Medicine (TCM) to holistically treat neurocognitive disorders and also infectious diseases which affects the immune system such as COVID-19.
The company have been researching and conducting studies to address the fundamental causes of ADHD and ASD disorders. The goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the treatment of these disorders. $rgc aim to achieve improvements in both symptoms and overall health of patients as compared to currently available medications in the market. They are passionate about transforming the lives of patients, their families and caregivers and help them feel their best physically, mentally and emotionally!
RGC’s steady share price ascension in recent weeks may be a sign of greater things to come as its moves towards commercialization, we are encouraged by its thoughtful, systematic approach to developing its therapies, and communicating its progress to shareholders.
https://www.nasdaq.com/articles/2-biotech-sto...2021-10-17
